ArticleEuropean radiology2026
CT-derived extracellular volume fraction as a predictive marker for postoperative recurrence in pStage II-III gastric cancer.
Article in European radiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Computed tomography-derived extracellular volume fraction is associated with high-grade recurrence in non-muscle-invasive bladder cancer treated with intravesical gemcitabine and docetaxel.BJU international · 2026Article
- Delayed phase dual-energy CT for early peritoneal metastasis prediction: imaging phenotypes and tumor-stroma correlates in upfront gastrectomy candidates.Abdominal radiology (New York) · 2026Article
- Dual-energy computed tomography-derived extracellular volume fraction and spectral quantitative parameters for predicting early recurrence after gastrectomy: insights from a multicenter study.Abdominal radiology (New York) · 2026Article
- Prediction of long-term survival in gastric cancer patients after immunotherapy based on CT-derived extracellular volume fraction.Frontiers in oncology · 2025Article
Corrections and comments
- Erratum issued
Authors and funding
8 authors.
Funding
Abstract
objectiveThis study assessed the prognostic value of CT-derived extracellular volume fraction (CT-ECV) in predicting postoperative recurrence in patients with pathological stage (pStage) II-III gastric cancer (GC). MATERIALS AND
methodsA retrospective analysis was conducted on 112 patients with pathologically confirmed pStage II-III gastric adenocarcinoma who underwent preoperative triphasic contrast-enhanced CT and curative gastrectomy without neoadjuvant therapy. The relationship between preoperative CT-ECV and recurrence risk was evaluated using comprehensive imaging and clinicopathological data. The optimal CT-ECV threshold for recurrence prediction was determined using receiver operating characteristic (ROC) curve analysis. Disease-free survival (DFS) was assessed using Kaplan-Meier and Cox regression analyses.
resultsThe mean CT-ECV was 56.4 ± 16.7%. Patients with recurrence (n = 28) had significantly higher CT-ECV values than those without recurrence (n = 84) (65.3 ± 14.3% vs 53.5 ± 16.5%; p < 0.001). The optimal CT-ECV cutoff for recurrence prediction was ≥ 56.9%, with an area under the curve of 0.71 (sensitivity 82.1%, specificity 61.9%). Multivariate analysis revealed that high CT-ECV was independently associated with worse DFS (HR: 5.93; 95% CI: 1.77-19.86; p = 0.004). Patients with high CT-ECV had significantly lower DFS rates compared to those with low CT-ECV (5-year DFS rate: 49.9% vs 93.7%; p < 0.001).
conclusionHigh CT-ECV values correlate with increased recurrence risk and shorter DFS in pStage II-III GC, highlighting its potential as a predictive imaging biomarker for preoperative risk stratification. KEY POINTS: Question Identifying prognostic markers is crucial for improving outcomes in stage II-III GC with high recurrence rates post-treatment. Findings High preoperative CT-ECV values are independently associated with increased recurrence risk and reduced DFS in pStage II-III GC. Clinical relevance CT-ECV can facilitate personalised treatment strategies and potentially improve patient management and outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.